Physiology and pathophysiology of the vasopressinergic system

Best Practice and Research: Clinical Anaesthesiology

Volumn 22, Issue 2, 2008, Pages 243-252

  Vincent, Jean Louis ^a   Su, Fuhong ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

diabetes insipidus; hyponatraemia; SIADH; thirst; water regulation

Indexed keywords

CORTICOTROPIN; DESMOPRESSIN; G PROTEIN COUPLED RECEPTOR; INSULIN; OXYTOCIN; TOLVAPTAN; UREA; VASOPRESSIN; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR ANTAGONIST;

AMINO TERMINAL SEQUENCE; ASCITES; BLOOD PRESSURE REGULATION; BODY WATER; CARBOXY TERMINAL SEQUENCE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORTICOTROPIN RELEASE; DECOMPENSATED LIVER CIRRHOSIS; DIABETES INSIPIDUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FLUID INTAKE; HOMEOSTASIS; HORMONE ACTION; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INSULIN RELEASE; LOW DRUG DOSE; NEGATIVE FEEDBACK; NEUROENDOCRINE DISEASE; NEUROENDOCRINE SYSTEM; OSMOREGULATION; PATHOPHYSIOLOGY; PLASMA OSMOLALITY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECOND MESSENGER; SEPTIC SHOCK; SOCIAL BEHAVIOR; THERMOREGULATION; VASOPRESSIN RELEASE; WATER RETENTION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, VASOPRESSIN; VASOPRESSINS;

EID: 44949090322     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2008.03.004     Document Type: Review

References (48)

1. Oliver G., and Schaefer E.A. On the physiological action of extract of pituitary body and certain other glandular organs. The Journal of Physiology 18 (1895) 277-279
2. Mutlu G.M., and Factor P. Role of vasopressin in the management of septic shock. Intensive Care Medicine 30 (2004) 1276-1291
3. Oshikawa S., Tanoue A., Koshimizu T.A., et al. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Molecular Pharmacology 65 (2004) 623-629
4. Tanoue A., Ito S., Honda K., et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. The Journal of Clinical Investigation 113 (2004) 302-309
5. Weingartner H., Gold P., Ballenger J.C., et al. Effects of vasopressin on human memory functions. Science 211 (1981) 601-603
6. Bielsky I.F., Hu S.B., Ren X., et al. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron 47 (2005) 503-513
7. Acher R., Chauvet J., and Chauvet M.T. Man and the chimaera. Selective versus neutral oxytocin evolution. Advances in Experimental Medicine and Biology 395 (1995) 615-627
8. de Bree F.M., and Burbach J.P. Structure-function relationships of the vasopressin prohormone domains. Cellular and Molecular Neurobiology 18 (1998) 173-191
9. Sklar A.H., and Schrier R.W. Central nervous system mediators of vasopressin release. Physiological Reviews 63 (1983) 1243-1280
10. Baylis P.H. Osmoregulation and control of vasopressin secretion in healthy humans. American Journal of Physiology 253 (1987) R671-R678
11. Feldberg W., Guertzenstein P.G., and Rocha e Silva Jr. M. Vasopressin release by nicotine: the site of action. British Journal of Pharmacology 54 (1975) 463-474
12. den Ouden D.T., and Meinders A.E. Vasopressin: physiology and clinical use in patients with vasodilatory shock: a review. Netherlands Journal of Medicine 63 (2005) 4-13
13. Kam P.C., Williams S., and Yoong F.F. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 59 (2004) 993-1001
14. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovascular Research 51 (2001) 372-390
15. Quillen Jr. E.W., and Cowley Jr. A.W. Influence of volume changes on osmolality-vasopressin relationships in conscious dogs. American Journal of Physiology 244 (1983) H73-H79
16. Schrier R.W., Berl T., and Anderson R.J. Osmotic and nonosmotic control of vasopressin release. American Journal of Physiology 236 (1979) F321-F332
17. Leng G., Brown C.H., and Russell J.A. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Progress in Neurobiology 57 (1999) 625-655
18. Bahr V., Franzen N., Oelkers W., et al. Effect of exogenous glucocorticoid on osmotically stimulated antidiuretic hormone secretion and on water reabsorption in man. European Journal of Endocrinology 155 (2006) 845-848
19. Birnbaumer M. Vasopressin receptors. Trends in Endocrinology and Metabolism 11 (2000) 406-410
20. Oakley R.H., Laporte S.A., Holt J.A., et al. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. The Journal of Biological Chemistry 274 (1999) 32248-32257
21. Barberis C., Mouillac B., and Durroux T. Structural bases of vasopressin/oxytocin receptor function. The Journal of Endocrinology 156 (1998) 223-229
22. Birnbaumer M., Seibold A., Gilbert S., et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 357 (1992) 333-335
23. Chini B., and Manning M. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. Biochemical Society Transactions 35 (2007) 737-741
24. Neves S.R., Ram P.T., and Iyengar R. G protein pathways. Science 296 (2002) 1636-1639
25. Holmes C.L., Landry D.W., and Granton J.T. Science review: vasopressin and the cardiovascular system part 1 - receptor physiology. Critical Care (London, England) 7 (2003) 427-434
26. George C.P., Messerli F.H., Genest J., et al. Diurnal variation of plasma vasopressin in man. The Journal of Clinical Endocrinology and Metabolism 41 (1975) 332-338
27. Nadal M. Secretory rhythm of vasopressin in healthy subjects with inversed sleep-wake cycle: evidence for the existence of an intrinsic regulation. European Journal of Endocrinology 134 (1996) 174-176
28. Forrest P. Vasopressin and shock. Anaesthesia and Intensive Care 29 (2001) 463-472
29. Williams T.D., Da Costa D., Mathias C.J., et al. Pressor effect of arginine vasopressin in progressive autonomic failure. Clinical Science (London) 71 (1986) 173-178
30. Peters H.P., Robben J.H., Deen P.M., and Wetzels J.F. Water in health and disease: new aspects of disturbances in water metabolism. Netherlands Journal of Medicine 65 (2007) 325-332
31. Robertson G.L. Abnormalities of thirst regulation. Kidney International 25 (1984) 460-469
32. Bartter F.C., and Schwartz W.B. The syndrome of inappropriate secretion of antidiuretic hormone. American Journal of Medicine 42 (1967) 790-806
33. Multz A.S. Vasopressin dysregulation and hyponatremia in hospitalized patients. Journal of Intensive Care Medicine 22 (2007) 216-223
34. Rai A., Whaley-Connell A., McFarlane S., and Sowers J.R. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. American Journal of Nephrology 26 (2006) 579-589
35. Soupart A., Gross P., Legros J.J., et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clinical Journal of the American Society of Nephrology 1 (2006) 1154-1160
36. Goldsmith S.R. The role of vasopressin in congestive heart failure. Cleveland Clinic Journal of Medicine 73 Suppl 3 (2006) S19-S23
37. Kalra P.R., Anker S.D., and Coats A.J. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovascular Research 51 (2001) 495-509
38. Chin M.H., and Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Archives of Internal Medicine 156 (1996) 1814-1820
39. Klein L., O'Connor C.M., Leimberger J.D., et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111 (2005) 2454-2460
40. Kumar S., Rubin S., Mather P.J., and Whellan D.J. Hyponatremia and vasopressin antagonism in congestive heart failure. Clinical Cardiology 30 (2007) 546-551
41. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. The Journal of the American Medical Association 297 (2007) 1319-1331
42. Gines P., Berl T., Bernardi M., et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 28 (1998) 851-864
43. Morello J.P., Salahpour A., Laperriere A., et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. The Journal of Clinical Investigation 105 (2000) 887-895
44. Holmes C.L., Landry D.W., and Granton J.T. Science review: vasopressin and the cardiovascular system part 2 - clinical physiology. Critical Care (London, England) 8 (2004) 15-23
45. Landry D.W., Levin H.R., Gallant E.M., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 (1997) 1122-1125
46. Sharshar T., Blanchard A., Paillard M., et al. Circulating vasopressin levels in septic shock. Critical Care Medicine 31 (2003) 1752-1758
47. Sharshar T., Carlier R., Blanchard A., et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Critical Care Medicine 30 (2002) 497-500
48. Vincent J.L. Vasopressin in hypotensive and shock states. Critical Care Clinics 22 (2006) 187-197